Endurance exercise attenuates cardiotoxicity induced by androgen deprivation and doxorubicin

被引:10
作者
Parry, Traci L. [1 ,2 ]
Hydock, David S. [1 ,2 ]
Jensen, Brock T. [3 ]
Lien, Chia-Ying [4 ]
Schneider, Carole M. [1 ,2 ]
Hayward, Reid [1 ,2 ]
机构
[1] Univ No Colorado, Sch Sport & Exercise Sci, Greeley, CO 80639 USA
[2] Univ No Colorado, Rocky Mt Canc Rehabil Inst, Greeley, CO 80639 USA
[3] Slippery Rock Univ, Dept Exercise & Rehabil Sci, Slippery Rock, PA 16057 USA
[4] Natl Taiwan Univ, Athlet Dept, Taipei 10617, Taiwan
关键词
androgen deprivation therapy; cardiotoxicity; doxorubicin; endurance training; exercise; heart; MYOSIN HEAVY-CHAIN; CARDIAC-FUNCTION; POWER OUTPUT; IN-VIVO; ISOFORM EXPRESSION; PROSTATE-CANCER; RAT; THERAPY; PROTECTS; MYOCYTES;
D O I
10.1139/cjpp-2013-0294
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Doxorubicin (DOX) is associated with cardiac dysfunction and irreversible testicular damage. Androgen deprivation therapy (ADT) is administered prior to DOX treatment to preserve testicular function. However, ADT may exacerbate DOX-induced cardiac dysfunction. Exercise is cardioprotective, but the effects of exercise on cardiac function during combined ADT and DOX treatment are currently unknown. In this study, male Sprague-Dawley rats were randomly assigned to experimental groups: control (CON), ADT, DOX, or ADT+DOX. Animals received ADT or control implants on days 1 and 29 of the 56-day protocol. Animals remained sedentary (SED) or engaged in treadmill endurance exercise (TM) beginning on day 1. On day 15, the animals received DOX at 1 mg.(kg body mass)(-1).d(-1) by intraperitoneal injection for 10 consecutive days, or an equivalent volume of saline. On day 57, cardiac function was assessed in vivo and ex vivo. Animals treated with DOX alone, or with combined ADT+DOX, showed significant (P < 0.05) reductions in left ventricular developed pressure (-21% and -27%), maximal rate of pressure development (-29% and -32%), and maximal rate of pressure decline (25% and 31%), respectively when compared with the sedentary control animals. Endurance exercise training attenuated (P > 0.05) cardiac dysfunction associated with combined ADT+DOX treatment, indicating that exercise during simultaneous ADT+DOX treatment is cardioprotective.
引用
收藏
页码:356 / 362
页数:7
相关论文
共 44 条
[1]   Cardiovascular Toxicity of Androgen Deprivation Therapy: A New Door Opens [J].
Alibhai, Shabbir M. H. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (26) :3500-3502
[2]   A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer [J].
Amato, Robert ;
Stepankiw, Mika ;
Gonzales, Patricia .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (06) :1629-1634
[3]  
Arango M., 2006, ENDOCRINOLOGY, V147, P5967, DOI [10.1210/en.2006-0728, DOI 10.1210/EN.2006-0728]
[4]  
Aversa Antonio, 2012, Front Endocrinol (Lausanne), V3, P17, DOI 10.3389/fendo.2012.00017
[5]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[6]   Altered in vivo left ventricular torsion and principal strains in hypothyroid rats [J].
Chen, Yong ;
Somji, Aleefia ;
Yu, Xin ;
Stelzer, Julian E. .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2010, 299 (05) :H1577-H1587
[7]   Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart [J].
Chicco, AJ ;
Schneider, CM ;
Hayward, R .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2005, 289 (02) :R424-R431
[8]   Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity [J].
Chicco, AJ ;
Hydock, DS ;
Schneider, CM ;
Hayward, R .
JOURNAL OF APPLIED PHYSIOLOGY, 2006, 100 (02) :519-527
[9]   Androgen modulates cardiac fibrosis contributing to gender differences on heart failure [J].
Chung, Cheng-Chih ;
Kao, Yu-Hsun ;
Chen, Yu-Ju ;
Chen, Yi-Jen .
AGING MALE, 2013, 16 (01) :22-27
[10]   THE MOLECULAR PHARMACOLOGY OF DOXORUBICIN INVIVO [J].
CUMMINGS, J ;
ANDERSON, L ;
WILLMOTT, N ;
SMYTH, JF .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (05) :532-535